APA (7th ed.) Citation

Stock, S., Übelhart, R., Schubert, M., Fan, F., He, B., Hoffmann, J., . . . Sellner, L. (2019). Idelalisib for optimized CD19-specific chimeric antigen receptor T cells in chronic lymphocytic leukemia patients. International journal of cancer, 145(5), .

Chicago Style (17th ed.) Citation

Stock, Sophia, et al. "Idelalisib for Optimized CD19-specific Chimeric Antigen Receptor T Cells in Chronic Lymphocytic Leukemia Patients." International Journal of Cancer 145, no. 5 (2019).

MLA (9th ed.) Citation

Stock, Sophia, et al. "Idelalisib for Optimized CD19-specific Chimeric Antigen Receptor T Cells in Chronic Lymphocytic Leukemia Patients." International Journal of Cancer, vol. 145, no. 5, 2019.